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ABSTRACT 
 
Objectives: This study aimed to explore the adverse effects of chemotherapeutic agents used in the treatment of 
ovarian and cervical cancer by analysing patients’ views posted in online discussion fora. 
 
Method: UK-centred online discussion fora were used to identify discussion threads on ovarian and cervical 
cancer between 2008 and 2017. The study was approved by the University of Bournemouth ethics committee. 
283 discussion threads with 644 participants from four online discussion fora (Cancer Research UK, Macmillan, 
Ovacome and Jo’s Cervical Cancer Trust) were identified. The threads were exported into NVivo and a thematic 
content analysis was conducted to identify study themes.  
 
Results: Of the 644 participants, 19.4% had a diagnosis of cervical cancer and 80.6% had a diagnosis of ovarian 
cancer. Four main themes related to: 1) treatment plan, 2) adverse effects, 3) perception of treatment and 4) 
hospitalisation were identified. Patients’ perception about their treatment was reported to be positive across all 
chemotherapeutic agents. 312 adverse effects were reported by cervical cancer patients taking Cisplatin with 
fatigue (52.1%) and nausea (30.6%) being the two most frequently reported adverse effects. With regards to the 
treatment of ovarian cancer, 402 adverse effects were reported by patients on carboplatin and paclitaxel with 
neuropathy (29.3%) and fatigue (28.0%) being the two commonly reported adverse effects. 
 
Conclusion: The online discussion fora allowed patients to express their concerns in a blame free environment 
that provided novel insight into the impact of chemotherapy associated adverse effects on patients with cervical 
and ovarian cancers. Real-life experiences shared by patients can help the healthcare professionals find the right 
balance between the prolonged survival and quality of life. 
 
Key words: Cervical cancer, ovarian cancer, adverse effects. 
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INTRODUCTION  
  
The Internet has become an increasingly important source of knowledge for both patients and doctors. For 
example, the United States witnessed a steady drop in the offline population from 48% in the year 2000 to a 
mere 13% in 2016.[1] Such high usage of internet has also been reported in Europe with an estimated 78% of 
the Europeans using internet in the last three months.[2] Furthermore, for some, online resources have 
progressively become the first point of information for specific conditions such as cancer.[3]   
  
Cancer is a worldwide problem that has a high mortality rate accounting for 70% of deaths in the low and 
middle-income countries.[4] Ovarian cancer representing 4% of all cancers in women is known as the ‘silent 
killer’ that often goes undetected and is diagnosed at an advanced stage which requires an aggressive medical 
protocol.[5-6] A recent study involving 2,498 patients with epithelial ovarian cancer reported that the mean age 
of patients at diagnosis was 52.8 and an earlier diagnosis would have led to a better survival rate.[7] Incidences 
of ovarian cancer are reported to be highest in the Europe and United States (US).[8] Cervical cancer is another 
prevalent gynaecological cancer that is expected to affect one in 135 women in their lifetime.[9] However, the 
earlier detection of cervical cancer with a likely achievement of remission gives it a better prognosis than 
ovarian cancer.[10] Although, there are similarities in both gynaecological cancers, yet there are key differences 
in their demography and treatment plans.  
  
Online discussion fora allow patients to gather support, reassurance and knowledge by exchanging information 
with other patients.[11-12]. Furthermore, online discussion boards and support groups can highlight the adverse 
effects of therapeutic agents that may not be discernible in clinical trials thus providing a good insight into the 
adverse effects from the patients’ perspectives.[13] Although, previous studies have identified the adverse 
effects of chemotherapeutic agents through patient records or clinical trials, little has been done to explore the 
incidence of adverse effects from the patients’ perspective.[14-16] Furthermore, there is a need to explore how 
patients perceive and relate their experience of adverse effects with chemotherapeutic agents used in the 
treatment of cervical and ovarian cancers. This study, therefore, aims to explore patients’ perception about 
adverse effects and its impact on their quality of life.   
 
 
METHODS 
 
This qualitative study involved a thematic content analysis of qualitative data using ovarian and cervical cancer 
online discussion fora.   
  
Ethical considerations  
 
The study adhered to the ethical regulations stated in the declaration of Helsinki. The General Data Protection 
Regulation (GDPR) was also followed; therefore, no identifiable data of patients were collected from the 
discussion fora.[17] Furthermore, any features that could identify participants such as real names were excluded 
from the study. In addition, URL addresses of the included forums were also excluded to make the identification 
of the original threads more difficult. The research was approved by the University of Bournemouth ethics 
committee (BU 21652).   
  
Data sources  
 
Search was conducted to identify public online fora that discussed chemotherapeutic agents used in the 
treatment of cervical and ovarian cancer. Keywords included “cervical cancer” or “ovarian cancer” AND 
“online forum”. The search and analysis were conducted in March 2018 and included threads posted between 
January 2008 and end November 2017. Only threads from UK fora were included to ensure the application of 
2018 National Institute for Health and Care Excellence (NICE) guidelines. Included threads had to be active 
with a minimum of one post and one reply. Posts from patients themselves or posts made on behalf of direct 
relatives including mother, father, child, sibling and spouse were eligible for inclusion. Posts on behalf of 
patients’ grandparents, uncles, auntie’s friends or distant relatives were excluded from the study. Threads from 
international fora were also excluded. The threads were saved as PDF files in order to preserve the format of the 
post exactly how they were written. This meant the time and date of the post was clearly visible and ensured the 
files were in a suitable format to be uploaded to NVivo Pro 11 for analysis.   
  
The search returned 2,900,000 results for cervical cancer and 1,200,000 for ovarian cancer. Of these, four UK-
based online fora were identified: cancerresearchuk.org, jostrust.org.uk, macmillan.org.uk and ovacome.org.uk. 
4 
 
Thematic analysis  
 
A thematic analysis was conducted to explore patients’ written comments. All comments were first read line-by-
line twice to become familiar with the threads before the analysis was carried out. No restriction was put on the 
length of the code and this ranged from a word, sentence or paragraph, however, this was taken within the 
context of the whole thread.[18] The text was checked for themes and patterns, which could then be coded into 
different themes and sub-themes. Threads were then read again to make sure that no comments in relation to the 
created themes had been missed in order to maintain consistency. Summary tables were then created containing 
all relevant quotes, split into relevant themes and sub-themes. Quotations were grammatically edited for ease of 
understanding, ensuring the style and structure of the sentence or paragraph was maintained. 
 
 
RESULTS 
 
A total of 1758 pages of text were generated, 441 pages for patients with cervical cancer and 1317 pages for 
patients with ovarian cancer. From the 272 threads, there were 644 contributors, 125 with cervical cancer and 
519 with ovarian cancer (see appendix 1 for the included threads). All participants in the study were female due 
to the nature of the disease. 19 Individuals with cervical cancer reported their age, which ranged from 25 to 71 
years old with a median of 36 years old. 12 individuals with ovarian cancer reported their age, which ranged 
from 41 to 71 years old with a median of 50.5 years old. Four main themes related to: 1) treatment plan, 2) 
adverse effects, 3) perception of treatment and 4) hospitalisation were identified (see table 1 for themes, sub-
themes and supporting quotations). 
 
Treatment plan 
 
660 drugs or drug combinations were reported by the participants (Tables 2.1 and 2.2). 
 
 
Table 2.1: Treatment plan of chemotherapeutic agents administered in cervical cancer patients 
 
Drug Number Frequency (%) 
Cisplatin 121 96.8 
Cisplatin and Topotecan 4 3.20 
 
Table 2.2: Treatment plan of chemotherapeutic agents administered in ovarian cancer patients 
 
Drug 
          
Number  Frequency (%) 
Carboplatin and  232 43.4 
Paclitaxel    
Carboplatin  90 16.8 
PLDH  55 10.3 
Carboplatin and  53 9.91 
Gemcitabine    
Carboplatin and PLDH  48 8.97 
Paclitaxel  34 6.36 
Cisplatin  16 2.99 
Topotecan  3 0.561 
Cisplatin and Paclitaxel  3 0.561 
PLDH and Cisplatin  1 0.187  
 
PLDH: Pegylated Liposomal Doxorubicin Hydrochloride 
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24 (19.2%) cervical cancer patients reported the duration of treatment. This ranged from four to six weeks with 
the most frequently reported treatment length being 5 weeks, stated by 17 patients (70.8%). 32 (6.17%) ovarian 
cancer patients reported the duration of treatment. This ranged from 12 to 24 weeks with the most frequently 
reported treatment length being 18 weeks, stated by 24 patients (75.0%).67 (53.6%) cervical cancer patients 
recorded the number of doses administered, ranging from four to six doses. The most commonly reported 
dosage was five, reported by 46 patients (68.7%).   
  
110 (88.0%) cervical cancer patients reported that they received nonchemotherapeutic agents as part of their 
treatment plan.104 patients reported receiving radiotherapy (83.2%), 62 reported specifically receiving 
brachytherapy (49.6%) and just one reported having surgery (0.8%). One individual said:  
  
  
“Treatment is five cisplatin, 25 radiotherapies, three Brachytherapy” (Thread JCTC17). 
 
Adverse effects  
  
312 adverse effects were reported in patients on cisplatin (see table 3.1 for adverse effects reported by patients 
on cisplatin). The bodily system most affected was the central nervous system (CNS), 222 adverse effects were 
classified within the system (71.2%). The most frequent adverse effect was fatigue, reported by 63 patients 
(52.1%), 37 patients felt nauseous (30.6%), 19 felt anxious (15.7%), 14 felt depressed (11.6%), 13 had tinnitus 
(10.7%), ten had a change in appetite (8.26%), eight experienced hypogeusia (6.61%) and four reported 
peripheral neuropathy (3.31%). Some of the less reported adverse effects included lack of concentration, 
insomnia, headache and numbness. One patient said:  
  
  
“I will say you will feel tired a deep heavy tired and you need to be kind to yourself and get rest when you 
can“(Thread MOCC03)  
  
The second most affected bodily system was the gastrointestinal tract (GIT) with 48 adverse effects classified 
within the system (15.3%). The most frequent adverse effect was diarrhoea, reported by 22 patients (18.9%), 
nine had heartburn (7.44%), six experienced constipation (4.96%) and five had indigestion (4.13%). Some of the 
less reported adverse effects included faecal incontinence, flatulence and bloody discharge. Another patient said:  
  
  
“I was not too tired but suffered with diarrhoea, but once I figured out the right way to manage that I was ok.” 
(Thread JCTC18)  
  
 
Table 3.1: Adverse effects experienced by participants on cisplatin, classified into bodily system  
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System Adverse effect Number  Percentage% 
CNS Fatigue  63 52.1 
 Nausea  37 30.6 
 Lack of Alopecia  35 28.9 
 Anxiety  19 15.7 
 Depression  14 11.6 
 Tinnitus  13 10.7 
 General feeling of   9.09 
 Unwellness  11 
 Change in appetite  10 8.3 
 Hypogeusia  8 6.6 
 Peripheral  4 3.3 
 Neuropathy    
 Lack of  3 2.4 
 Concentration    
 Insomnia  2 1.6 
 Headache  2 1.6 
 Numbness  1 0.8 
GIT Diarrhoea  22 18.2 
 Heartburn  9 7.4 
 Constipation  6 4.9 
 Indigestion  5 4.3 
 Faecal Incontinence  3 2.4 
 Flatulence  2 1.6 
 Bloody Discharge  1 0.8 
Renal Cystitis  5 4.1 
 Kidney Damage  4 3.3 
 Increased Urination  2 1.6 
 Dysuria  2 1.6 
Circulatory Anaemia  10 8.2 
 Thrombocytopenia  1 0.8 
Allergies Rash  7 5.7 
Muscle Musculoskeletal pain  5 4.1 
Immune Neutropenia  4 3.3 
 
  
402 adverse effects were reported in patients on carboplatin and paclitaxel (see Table 3.2 for adverse effects 
reported by patients on carboplatin and paclitaxel). The bodily system most affected was the CNS, 257 adverse 
effected were classified within the system (63.9%). The most frequent adverse effect was neuropathy, reported 
by 68 patients (29.3%), 65 had fatigue (28.0%), 45 experienced alopecia (19.4%), 34 felt nauseous (14.7%), 22 
reported vomiting (9.48%), eight had tinnitus (3.45%) eight had dysuria (3.45%). Some of the less reported 
adverse effects included nosebleeds, loss of appetite and hypogeusia. 
 
Table 3.2: Adverse effects experienced by participants on the combined chemotherapeutic agents 
carboplatin and paclitaxel, classified into bodily system 
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System Adverse effect Number  Percentage % 
CNS Neuropathy  68 29.3 
 Fatigue  65 28.0 
 Alopecia  45 19.4 
 Nausea  34 14.7 
 Vomiting  22 9.4 
 Tinnitus  8 3.4 
 Dysuria  8 3.4 
 Nosebleed  3 0.9 
 Loss of appetite  2 0.8 
 Hypogeusia  2 0.8 
GIT Constipation  15 6.4 
 Abdominal pain  14 6.0 
 Pelvic bloating  4 1.7 
 Indigestion  4 1.7 
 Faecal incontinence  4 
    1.7 
 Pelvic pain  2 0.8 
Muscle Myasthenia  23 9.9 
 Myalgia  12 5.1 
 Backache  3 0.9 
Allergies Rash  14 6.0 
 Allergic reaction  3 0.9 
 Anaphylaxis  2 0.8 
 Swelling  2 0.8 
Immune Neutropenia  8 3.5 
 Sore mouth  3 0.9 
 Infection  1 0.4 
Circulatory Anaemia  8 3.4 
 Hypertension  1 0.4 
 Blood clot  1 0.4 
Skeletal Bone pain  6 2.5 
Brain Headache  3 0.9 
 Emotional  1 0.4 
Renal Bladder incontinence  1 0.4 
 Unable to pass urine  1 0.4 
 Urinary irritation  1 0.4 
     
Other General feeling of  3 0.9 
 unwellness    
 Sinus problems  2 0.8 
 Hoarse voice  1 0.4 
 Sore Gums  1 0.4 
 Endocrine dysfunction  1  
    0.4 
 
CNS: Central Nervous System GIT: Gastrointestinal Tract   
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Hospitalisation 
  
One patient taking cisplatin for cervical cancer reported hospitalisation. The patient said:  
  
 “Thanks for the messages! I have been admitted to hospital as I have been 2 days without anything to eat and 
hardly any fluids.” (Thread JCTC14 page 4)  
  
  
There were no reports of hospitalisation in the combined treatment of cisplatin and topotecan used to treat 
cervical cancer. Seven patients on carboplatin and paclitaxel for the treatment of ovarian cancer reported 
hospitalisation (1.3%). Three patients on PLDH as a single-agent, three on the combination treatment of 
carboplatin and gemcitabine (0.5%) and three on cisplatin and topotecan (0.578%) reported hospitalisation. Less 
reported cases of hospitalisation were recorded in carboplatin, cisplatin as single-agents and the combined 
agents carboplatin and PLDH. One patient said:  
  
“Ended up in hospital after last chemotherapy with high temp and the last chemotherapy took a lot out of me so 
I didn't go on holiday in the end!” (Thread OVC19 page 6)  
 
 
Perception of treatment 
 
Overall the treatment was perceived as positive with 23 patients on cisplatin saying the treatment was 
manageable with medication (74.2%) and the other eight reporting the treatment was not as bad as expected 
(25.8%). One patient said:  
  
  
“Overall to be fair it has been manageable had a couple of turns of bowels but again manageable and took some 
Imodium and drinking gallons of water.” (Thread JCTC04)  
  
57 patients on carboplatin and paclitaxel (27.0%) reported their perception of treatment. 36 reported the 
treatment was manageable (63.2%), 15 reported it was difficult to cope with (26.32%), five felt it was 
manageable with treatment of adverse effects (8.77%) and one patient reported having a positive perception. 
One patient said:  
  
  
“I've found the whole thing surprisingly bearable.” (Thread MOCO11) 
  
  
Table 1. Themes and subthemes with supporting quotations 
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Themes Subthemes  Supporting Quotations 
Treatment plan Drug  “I had cisplatin in six once-a-week doses.” (Thread MOCC08)  
   “I received carboplatin and paclitaxel” (Thread CRO15)  
 Duration of  “I had my treatments over five weeks (weekends were off) radio 
 Treatment  every day and chemotherapy on a Wednesday” (Thread 
   MOCC11) 
   “Hi I'm on weekly paclitaxel at the moment and have just had 
   14th out of 18” (Thread OVC125) 
 Dosage  “Five weeks of chemotherapy and radiation on a Monday  
   (cisplatin).” (JCTC16)  
   “I think I had the same regime as you - carboplatin and Avastin  
   every three weeks, paclitaxel every week.” (Thread MOCO59)  
   “I had 25 daily radiotherapy sessions, five cisplatin,  
   chemotherapy and four brachytherapy.” (Thread MOCC12)  
   “I had surgery first then six rounds of carboplatin/paclitaxel,”  
   (Thread MOCO04)  
 Non-  “Treatment is five cisplatin, 25 radiotherapies, three 
 chemotherapeutic  Brachytherapy” (Thread JCTC17) 
 Agents  “I'm glad that you are on the 8b trial and that you have access to 
   the Avastin. I really think that it gives us the best chance.” 
   (Thread MOCO11) 
    
Adverse effects Cisplatin  “I will say you will feel tired a deep heavy tired and you need to 
   be kind to yourself and get rest when you can“ (Thread 
   MOCC03) 
   “I was not too tired but suffered with diarrhoea, but once I figured 
   out the right way to manage that I was ok.” (Thread JCTC18) 
   I developed cystitis two weeks after my treatment had finished and I 
   had it for about 10 days,” (Thread JCTC30) 
   “I was very anaemic at the start even after the blood and iron 
   transfusions and my HB was still low with just the Fe tabs to help 
   bump it up. “ (Thread JCTC03) 
   “I noticed numbness and tingling in my toes and fingers, and it 
   did not fade.” (Thread OVC88 page) 
   “My Dr is considering carboplatin now because not only was the 
   vomiting uncontrollable but I ended up in the hospital for 
   neutropenia fever.” (Thread OVC26) 
 Carboplatin and  “Massive constipation to the extent that she was hospitalised  
 Paclitaxel  twice from the pain and sickness.” (Thread MOCO80)  
   “I got a rash (amongst other reactions) when I had carboplatin  
   and paclitaxel chemotherapy.” (Thread MOCO85)  
   “Been admitted to hospital with neutropenia (boring rather than  
   dramatic),” (Thread MOCO41)  
 Carboplatin  “Cumulatively; tiredness grew with each treatment and 
   anaemia.” (Thread OVC14) 
   “I developed an allergy to carboplatin during the second 
   chemotherapy” (Thread MOCO02) 
   “The worst direct result of each treatment was constipation.” 
   (Thread OVC14) 
   “I did have to have a blood transfusion before I had my fifth 
   treatment as my bloods were so low” (Thread OVC03) 
   “I had aching limbs, tendonitis, needles and pins.” (Thread 
   OVC14) 
   Yes, I had headaches on carboplatin” (Thread OVC01) 
    
 PLDH  “I have never been so fatigued in my life ...I am sleeping and  
   sleeping and sleeping.” (Thread OVC123)  
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      “I too had a sore mouth and delays due to low blood counts,”  
      (Thread OVC63)  
 
       
      “I got indigestion but got around this by eating little and often”  
      (Thread OVC42)  
      “The side effect I had was soreness and itchiness on my legs.”  
      (Thread OVC23)  
   Paclitaxel  “I developed neuropathy in my feet and finger tips after the third 
      dose of paclitaxel at 75 %” (Thread OVC88) 
      “Both times I had nausea and diarrhoea with severe joint and 
      muscle pain.” (Thread OVC127) 
 
      
   Carboplatin and   “I have found the regime very tiring” (Thread OVC04)  
   Gemcitabine   “It hammered my bone marrow and so I had constant delays  
      because platelets were too low.” (Thread OVC04)  
      “My only problems were tiredness and low neutrophil count  
      twice,” (Thread OVC09)  
      “The constipation is worst” (Thread MOCO37)  
        
        
   Carboplatin and  “The tiredness is unreal it's an effort to do anything!!” (Thread 
   PLDH  OVC115) 
      “On the evening of day eight, I had stomach cramps so took 
      myself off to bed.” (Thread OVC104) 
      “All going ok have had a delay due to low neutrophils,” (Thread 
      OVC133) 
      “Mine didn't swell but the skin on my soles seemed thinner, 
      causing my feet to get sore if I walked far.” (Thread OVC56) 
        
        
   PLDH and cisplatin   “A recent change was skin itching and discolouration around bra  
 
     
side straps and armpits.” (Thread OVC96) 
 
       
 
       
        
 
     
“Ended up in hospital after last chemotherapy with high temp  
Hospitalisation 
    
 
  
and the last chemotherapy took a lot out of me so I didn't go on       
 
     
holiday in the end!” (Thread OVC19)       
 
     
“Thanks for the messages! I have been admitted to hospital as I       
 
     
have been 2 days without anything to eat and hardly any fluids.”       
 
     
(Thread JCTC14)       
        
 Perception of   “Overall to be fair it has been manageable had a couple of turns 
 treatment   of bowels but again manageable and took some Imodium and 
      drinking gallons of water.” (Thread JCTC04) 
      “I’m most worried about losing my hair” (Thread MOCO24) 
      “I've found the whole thing surprisingly bearable.” (Thread 
      MOCO11) 
      “I have had only a few side effects, all have been mild too, so 
      that has helped. I feel much better most of the time and can do 
      everything i have always done.” (Thread MOCO64) 
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DISCUSSION 
 
To authors’ knowledge, this is the first study that has qualitatively explored how patients perceive and relate 
their experience of adverse effects with chemotherapeutic agents when used alone or in combination. Real-life 
experiences shared by patients in this study provides novel insight into the impact of chemotherapy related 
adverse effects on patients with cervical and ovarian cancers. 
 
 
312 adverse effects were reported by patients taking cisplatin with fatigue and nausea being the two most 
frequently reported adverse effects. This corresponds with the adverse effects listed in the British National 
Formulary (BNF).[19] However, the BNF (2018) also lists alopecia as an adverse effect of cisplatin which was 
surprisingly not reported by patients in this study. Only a few patients reported experiencing some degree of 
renal toxicity with cisplatin which is consistent with the findings of previous studies that suggests that cisplatin 
is extremely nephrotoxic and can cause kidney failure.[20] However, the lower number of patients reporting 
nephrotoxicity in this study could be attributed to the patients receiving the correct therapeutic dose. 
Furthermore, several patients reported drinking large volumes of water in accordance with their doctor’s advice 
as preventative strategy.[21] With regards to the treatment of ovarian cancer, 402 adverse effects were reported 
by patients on carboplatin and paclitaxel with neuropathy and fatigue being the two commonly reported adverse 
effects. This is not unusual as the BNF (2018) lists peripheral neuropathy as a very common adverse effect 
associated with paclitaxel.[19]  
  
 
A large proportion of cervical cancer patients reported receiving radiotherapy with nearly half also reporting to 
receive brachytherapy. Although, radiotherapy increases the survival, it is often associated with acute and long-
term toxicity including urological, skin and CNS toxicity.[22] 48 patients reported to have received 
bevacizumab in combination with carboplatin and gemcitabine. Evidence suggests that the use of bevacizumab 
can improve the survival in advanced cervical cancer,[23] however, it has also been associated with increased 
mortality.[24] Stockley’s interactions state that although the pharmacokinetics is unaffected when combined 
with carboplatin, there is an increased risk of neutropenia. No drug-drug interaction has been reported between 
gemcitabine and bevacizumab.[25]  
  
  
The overall perception of patients about their treatment was overwhelmingly positive. Majority of the cervical 
cancer patients reported that although their treatment was difficult, yet it was manageable. Similarly, majority of 
patients with ovarian cancer also reported treatment as manageable with only few people reporting difficulties in 
coping with the treatment. Previous research suggested that the least favourable adverse effect was 
chemotherapy-induced nausea and vomiting.[26] However, in the current study, many patients reported that this 
was manageable with the antiemetics prescribed by their doctor. Although, cisplatin is considered highly 
cytotoxic, yet the overall perception of patients about cisplatin was positive. Many patients reported it was not 
as bad as they had anticipated and found their treatment to be manageable. Contrary to cisplatin, patients 
receiving carboplatin, carboplatin and paclitaxel, PLDH and carboplatin and gemcitabine reported some 
difficulties in coping with their treatment.  
  
 
This study has explored the adverse effects of chemotherapeutic agents from the patient’s perspective that 
allows healthcare professionals to develop a better understanding about the possible adverse effects in addition 
to the ones listed in the BNF. These findings can therefore help to improve the treatment of adverse effects 
associated with various chemotherapeutic agents. Furthermore, it provides a better understanding of the cost-
benefit analysis of cancer treatment, as well as help in finding the right balance between prolonged survival and 
quality of life. Future research could be conducted to identify less cytotoxic drugs with a larger therapeutic 
index to ensure the provision of more accurate dosage through personalised medicines. Since this study was 
limited to UK-based databases, future studies could extend to international discussion fora to determine if such 
findings are representative of patients worldwide. Furthermore, future research could use questionnaire or 
interview-based approaches to assess further outcomes including demography that often is not reported in online 
discussion fora.  
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This study has some limitations. It used a retrospective approach that suggests that it was not often possible to 
collect information on age, dosage and duration of treatment for every patient who posted on the discussion fora. 
Although, online discussion fora allow patients to share their experiences without any fear or harm, it may also 
lead to an overestimation of adverse effects experienced by the participants. Despite these study limitations, the 
use of online discussion fora provided vital information related to the treatment plan and toxicity of 
chemotherapeutic agents that is not available in the current literature.  
  
 
CONCLUSION 
 
The online discussion fora allowed patients to express their concerns in a blame free environment that provided 
novel insight into the impact of chemotherapy related adverse effects on patients with cervical and ovarian 
cancers. The findings of this study suggest the need to further improve the management of adverse effects 
experienced by patients with ovarian and cervical cancer. Further studies should be conducted to validate the 
findings of this study by comparing them with the results reported in experimental studies.  
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